JHW 007 hydrochloride
Dopamine uptake inhibitor; displays high affinity for the dopamine transporter (DAT) (Ki = 25 nM compared to 1330 and 1730 for NET and SERT respectively). Suppresses the effects of cocaine administration in a dose-dependent manner and decreases cocaine and methamphetamine self-administration in rats.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 421.95. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.37 mL||11.85 mL||23.7 mL|
|5 mM||0.47 mL||2.37 mL||4.74 mL|
|10 mM||0.24 mL||1.18 mL||2.37 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
References are publications that support the biological activity of the product.
Kristensen et al (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharm.Rev. 63 585
Kopajtic et al (2010) Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J.Pharmacol.Exp.Ther. 335 703 PMID: 20855444
Velaquez-Sanchez et al (2010) The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization. Eur.Neuropsychopharmacol. 20 501 PMID: 20413276
Hiranita et al (2014) Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J.Pharmacol.Exp.Ther. 348 174 PMID: 24194527
If you know of a relevant reference for JHW 007 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: JHW 007 hydrochloride, JHW 007 hydrochloride supplier, JHW007, dopamine, uptake, inhibitors, inhibits, DAT, transporter, Dopamine, Transporters, 4351, Tocris Bioscience
1 Citation for JHW 007 hydrochloride
Citations are publications that use Tocris products. Selected citations for JHW 007 hydrochloride include:
Andersen et al (2015) Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter. Stem Cell Reports 5 15650 PMID: 26503701
Do you know of a great paper that uses JHW 007 hydrochloride from Tocris? Please let us know.
Reviews for JHW 007 hydrochloride
There are currently no reviews for this product. Be the first to review JHW 007 hydrochloride and earn rewards!
Have you used JHW 007 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.